News

The Future of Drug and Therapeutic Testing and Validation


By Megan Bettilyon

Not all science leads to innovative outcomes – in fact, it’s rare when the day-to-day work of a wet-lab comes across something new. You can, however, stack the deck in your favor by encouraging yourself, and your team, to try something new. Push the boundaries of what is known and be willing to accept failure as a step toward success. You can choose to be innovative; you can choose to surround yourself with people who think differently. This is when the magic happens. This is where Terasaki recently found a way to change the game in how we can bring novel therapeutics to market faster, cheaper, and more effectively.

Smart Contact Lenses for Cancer Diagnostics and Screening



August 11, 2022

(LOS ANGELES)
– Scientists from the Terasaki Institute for Biomedical Innovation (TIBI) have developed a contact lens that can capture and detect exosomes, nanometer-sized vesicles found in bodily secretions which have the potential for being diagnostic cancer biomarkers. TThe lens was designed to have microchambers with antibodies that can capture exosomes found in tears. This antibody- conjugated signaling microchamber contact lens (ABSM-CL) can be stained for detection with nanoparticle-tagged specific antibodies for selective visualization. This offers a potential platform for cancer pre-screening and a supportive diagnostic tool that is easy, rapid, sensitive, cost-effective, and non-invasive.

Tissue Bioprinting for Biology and Medicine



August 10, 2022

(LOS ANGELES)
– In a recent paper published in Cell, TIBI scientist Mohsen Akbari, Ph.D., reviews the most recent breakthroughs and innovations in tissue bioprinting. He also presents its various applications, the remaining challenges and outlook for the future.

Read More

Destroying Tumor Cells: Targeted Immunotherapy Using Injectable Materials



August 1, 2022

(LOS ANGELES)
– Researchers at the Terasaki Institute for Biomedical Innovation (TIBI) have developed and optimized a minimally invasive method for more targeted, efficient, and sustained delivery of immunotherapeutic treatments for cancer. Such a targeted approach cuts down on the higher dosages and possible deleterious side effects that are experienced when more systemic treatment methods are employed.

Terasaki Institute for Biomedical Innovation and Openwater Form Collaboration



July 6, 2022

(LOS ANGELES)
– The Terasaki Institute for Biomedical Innovation (TIBI) has formally signed a collaborative agreement with San Francisco-based Openwater. TIBI, founded in 2020, fosters personalized medicine with their scientific research platforms for physiological models, devices, implants, cells, biomaterials and nutrition. They also incorporate business and technology transfer experts to adapt and develop their innovations for real-world use in the clinic.

Ovarian Cancer in the Fatty Omentum: Metabolic Enzyme’s Key Role in Tumor Metastasis



July 1, 2022

(LOS ANGELES)
– In their recent publication in Cell Reports, a team of scientists, led by Xiling Shen, Ph.D., Chief Scientific Officer at the Terasaki Institute for Biomedical Innovation (TIBI), has demonstrated the pivotal role of an enzyme, glucose-6-phosphate dehydrogenase (G6PD), in facilitating ovarian cancer (OC) growth and metastasis in the omentum, a curtain of fatty tissue found in the abdominal cavity.

TIBI Innovation-The Future of Drug and Therapeutic Testing and Validation


By Megan Bettilyon

Not all science leads to innovative outcomes – in fact, it’s rare when the day-to-day work of a wet-lab comes across something new. You can, however, stack the deck in your favor by encouraging yourself, and your team, to try something new. Push the boundaries of what is known and be willing to accept failure as a step toward success. You can choose to be innovative; you can choose to surround yourself with people who think differently. This is when the magic happens. This is where the Terasaki Institute for Biomedical Innovation (TIBI) recently found a way to change the game in how we can bring novel therapeutics to market faster, cheaper, and more effectively.

Self-plugging Microneedles Offer Potential to Improve Delivery of Drugs into the Eyeball

Published research on new eye treatment delivery shows improvement over hypodermic needles



June 17, 2022

(LOS ANGELES)
– A collaborative team, including scientists from the Terasaki Institute for Biomedical Innovation (TIBI), has developed a novel, self-plugging microneedle for injecting therapeutics into the eyes, potentially solving one of the major challenges of treating eye diseases – accurate delivery of therapeutic drugs to the retina, while guarding against possible complications at the injection site.